Analysts’ new coverage for Friday, January 5th:

Benchmark Co. initiated coverage on shares of Acasti Pharma (NASDAQ:ACST). They issued a speculative buy rating and a $7.00 target price on the stock.

Longbow Research began coverage on shares of Adient (NYSE:ADNT). They issued a neutral rating on the stock.

Longbow Research assumed coverage on shares of Autoliv (NYSE:ALV). Longbow Research issued a buy rating on the stock.

Credit Suisse Group AG assumed coverage on shares of Antero Midstream Partners (NYSE:AM). The firm issued an outperform rating and a $35.00 price target on the stock.

Longbow Research began coverage on shares of Aptiv (NYSE:APTV). Longbow Research issued a buy rating on the stock.

B. Riley initiated coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR). The firm issued a neutral rating and a $3.00 price target on the stock.

B. Riley initiated coverage on shares of Assembly Biosciences (NASDAQ:ASMB). B. Riley issued a neutral rating and a $35.00 price target on the stock.

Citigroup Inc started coverage on shares of CytomX Therapeutics (NASDAQ:CTMX). Citigroup Inc issued a buy rating and a $40.00 price target on the stock.

Credit Suisse Group AG began coverage on shares of EnLink Midstream Partners (NYSE:ENLK). They issued a neutral rating and a $16.00 target price on the stock.

Credit Suisse Group AG assumed coverage on shares of EQT Midstream Partners (NYSE:EQM). They issued a neutral rating and a $71.00 target price on the stock.

Roth Capital initiated coverage on shares of Fitbit (NYSE:FIT). They issued a buy rating and a $10.00 price target on the stock.

Longbow Research began coverage on shares of Gentex (NASDAQ:GNTX). They issued a buy rating on the stock.

Needham & Company LLC started coverage on shares of Juno Therapeutics (NASDAQ:JUNO). Needham & Company LLC issued a buy rating and a $65.00 price target on the stock.

Longbow Research initiated coverage on shares of Lear (NYSE:LEA). The firm issued a buy rating on the stock.

BTIG Research assumed coverage on shares of Luminex (NASDAQ:LMNX). BTIG Research issued a buy rating and a $24.00 price target on the stock.

BTIG Research assumed coverage on shares of Myriad Genetics (NASDAQ:MYGN). The firm issued a buy rating and a $41.00 target price on the stock.

Macquarie began coverage on shares of Nutrien (NYSE:NTR). They issued an outperform rating on the stock.

Credit Suisse Group AG assumed coverage on shares of Nutrien (NYSE:NTR). The firm issued a neutral rating and a $53.00 target price on the stock.

Raymond James Financial, Inc. started coverage on shares of Nutrien (NYSE:NTR). Raymond James Financial, Inc. issued a market perform rating and a $60.00 price target on the stock.

Bank of America Corp began coverage on shares of Nutrien (NYSE:NTR). They issued an underperform rating on the stock.

Credit Suisse Group AG assumed coverage on shares of Oasis Midstream Partners (NYSE:OMP). The firm issued a neutral rating and a $19.00 target price on the stock.

Leerink Swann began coverage on shares of Regulus Therapeutics (NASDAQ:RGLS). Leerink Swann issued an outperform rating and a $2.00 price target on the stock.

JMP Securities assumed coverage on shares of Sutherland Asset Management (NYSE:SLD). JMP Securities issued an outperform rating on the stock.

Roth Capital started coverage on shares of Semtech (NASDAQ:SMTC). Roth Capital issued a buy rating and a $39.00 price target on the stock.

Roth Capital started coverage on shares of Sequans Communications (NYSE:SQNS). Roth Capital issued a buy rating and a $4.00 price target on the stock.

Longbow Research started coverage on shares of Gentherm (NASDAQ:THRM). They issued an underperform rating on the stock.

Receive News & Ratings for Acasti Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.